(FORT WORTH, TX) — Michael E. Steadman, Group President and COO of DFB Branded Pharmaceuticals, a segment of Fort Worth, Texas-based DFB Pharmaceuticals, Inc., has announced that Perry M. Christensen has joined the company as Vice President, Human Resources for DFB Branded Pharmaceuticals. A multilingual, global HR executive, Mr. Christensen was most recently Director of Human Resources for Celanese Corporation, a chemical products company headquartered Dallas.

         Mr. Christensen will direct the human resources function for all of DFB’s branded businesses: Healthpoint, Ltd. and Coria Laboratories, Inc., both in Fort Worth; Phyton Biotech, Inc. in Princeton, NJ, and Phyton’s subsidiary, Phyton GmbH, based in Ahrensburg, Germany.

         The co-author of several books and articles concerning the balance between work, life and family, Mr. Christensen has work in publications that has been reviewed on such programs as Good Morning America, Fox News, and CNN.

         Mr. Christensen received a Bachelor of Science degree in organizational psychology from Brigham Young University and a Master of Science degree in organizational behavior from BYU’s J.W. Marriott School of Management.

         DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB’s business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for tissue management and surgical indications since 1992; and Coria Laboratories, Ltd., focusing on dermatology and treatments of diseases that affect the skin, hair, and nails. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world’s leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries; and Phyton’s German subsidiary, Phyton GmbH, which operates the world’s largest commercial cGMP manufacturing facility for plant cell fermentation. DFB is on the web at www.dfb.com.

###